Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FMXIN002 (epinephrine) is an adrenergic receptor agonist small molecule drug candidate, which is currently being evaluated for the treatment of anaphylaxis via intranasal spray.
Brand Name : FMXIN002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hypromellose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Taffix® Regains Marketing Approval in Spain
Details : Taffix powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.
Brand Name : TaffiX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 16, 2021
Lead Product(s) : Hypromellose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hypromellose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Taffix® Regains Marketing Approval in Spain
Details : Taffix® powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.
Brand Name : Taffix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 16, 2021
Lead Product(s) : Hypromellose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hypromellose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data from a prospective clinical post marketing users survey shows that TaffixTM effectively blocks viruses from reaching nasal mucosa and was able to reduce infection rate of SARS-CoV-2 virus after super spread event by at least 4 fold.
Brand Name : TaffiX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2020
Lead Product(s) : Hypromellose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hypromellose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Gel layer produced by TaffiX® powder after administration of a clinical equivalent amount, effectively blocked SARS-CoV-2 virus, as demonstrated by four log reduction in amount of viral RNA and reduced the amount of infectious live virus by more than 99...
Brand Name : TaffiX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 07, 2020
Lead Product(s) : Hypromellose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?